Advances in IKBKE as a potential target for cancer therapy.,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Advances in IKBKE as a potential target for cancer therapy.
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-11-15 , DOI: 10.1002/cam4.2678
Min Yin ₁ , Xin Wang _{2,

3} , Jie Lu ₄

Affiliation

IKBKE (inhibitor of nuclear factor kappa-B kinase subunit epsilon), a member of the nonclassical IKK family, plays an important role in the regulation of inflammatory reactions, activation and proliferation of immune cells, and metabolic diseases. Recent studies have demonstrated that IKBKE plays a crucial regulatory role in malignant tumor development. In recent years, IKBKE, an important oncoprotein in several kinds of tumors, has been widely found to regulate a variety of cytokines and signaling pathways. IKBKE promotes the growth, proliferation, invasion, and drug resistance of various cancers. This paper makes a detailed review that focuses on the recent discoveries of IKBKE in the malignant tumors, and puts forward that IKBKE is becoming an important therapeutic target for clinical treatment, which has been more and more realized.

中文翻译：

IKBKE 作为癌症治疗潜在靶点的进展。

IKBKE（核因子kappa-B激酶亚基ε抑制剂）是非经典IKK家族的成员，在炎症反应、免疫细胞活化和增殖以及代谢疾病的调节中发挥着重要作用。最近的研究表明IKBKE在恶性肿瘤的发生发展中发挥着至关重要的调节作用。近年来，IKBKE作为多种肿瘤中的重要癌蛋白，被广泛发现可调节多种细胞因子和信号通路。 IKBKE促进多种癌症的生长、增殖、侵袭和耐药性。本文对近年来IKBKE在恶性肿瘤中的发现进行了详细综述，提出IKBKE正在成为临床治疗的重要治疗靶点，并得到越来越多的认识。

更新日期：2019-11-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南